# Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

> **NCT02496286** · PHASE1 · TERMINATED · sponsor: **Eastern Regional Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- Malignant Ascites

## Interventions

- **DRUG:** Intraperitoneal Bevacizumab

## Key facts

- **NCT ID:** NCT02496286
- **Lead sponsor:** Eastern Regional Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 10 (ESTIMATED)
- **Why stopped:** Lack of Enrollment
- **Last updated:** 2017-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02496286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02496286, "Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02496286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*